Tuan Vu

8.5k total citations · 1 hit paper
92 papers, 2.4k citations indexed

About

Tuan Vu is a scholar working on Neurology, Molecular Biology and Clinical Biochemistry. According to data from OpenAlex, Tuan Vu has authored 92 papers receiving a total of 2.4k indexed citations (citations by other indexed papers that have themselves been cited), including 55 papers in Neurology, 24 papers in Molecular Biology and 18 papers in Clinical Biochemistry. Recurrent topics in Tuan Vu's work include Myasthenia Gravis and Thymoma (43 papers), Metabolism and Genetic Disorders (18 papers) and Mitochondrial Function and Pathology (17 papers). Tuan Vu is often cited by papers focused on Myasthenia Gravis and Thymoma (43 papers), Metabolism and Genetic Disorders (18 papers) and Mitochondrial Function and Pathology (17 papers). Tuan Vu collaborates with scholars based in United States, Italy and Germany. Tuan Vu's co-authors include Michio Hirano, Kurenai Tanji, S. DiMauro, Salvatore DiMauro, Clifton L. Gooch, Eduardo Bonilla, James F. Howard, Renato Mantegazza, E. Bonilla and Emily K. Plowman and has published in prestigious journals such as SHILAP Revista de lepidopterología, Blood and Hepatology.

In The Last Decade

Tuan Vu

87 papers receiving 2.4k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Long-term safety, tolerability, and efficacy of efgartigimod (ADAPT+): interim results from a phase 3 open-label extension study in participants with generalized myasthenia gravis

2024 36 citations James F. Howard, Vera Bril et al. profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Tuan Vu United States	27	1.2k	784	757	268	256	92	2.4k
Mika Leinonen United States	24	716 0.6×	815 1.0×	140 0.2×	55 0.2×	277 1.1×	43	2.2k
Sabrina Ravaglia Italy	25	362 0.3×	536 0.7×	117 0.2×	60 0.2×	191 0.7×	62	1.7k
Wendy J. Introne United States	19	664 0.5×	211 0.3×	657 0.9×	86 0.3×	38 0.1×	59	1.8k
Robert D. S. Pitceathly United Kingdom	25	1.2k 0.9×	136 0.2×	600 0.8×	40 0.1×	179 0.7×	75	1.6k
Lawrence A. Lockman United States	23	1.0k 0.8×	142 0.2×	494 0.7×	243 0.9×	91 0.4×	36	2.3k
Brahim Tabarki Saudi Arabia	24	567 0.5×	327 0.4×	288 0.4×	61 0.2×	155 0.6×	89	1.8k
Bernard Lemieux Canada	25	1.0k 0.8×	672 0.9×	361 0.5×	231 0.9×	550 2.1×	84	2.2k
Chantal Tallaksen Norway	29	604 0.5×	1.0k 1.3×	207 0.3×	290 1.1×	850 3.3×	77	2.3k
Michael Pike United Kingdom	24	459 0.4×	616 0.8×	51 0.1×	128 0.5×	186 0.7×	61	1.9k
Mary Kay Koenig United States	21	1.1k 0.9×	190 0.2×	677 0.9×	56 0.2×	167 0.7×	61	2.0k

Countries citing papers authored by Tuan Vu

Since Specialization

Citations

This map shows the geographic impact of Tuan Vu's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Tuan Vu with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Tuan Vu more than expected).

Fields of papers citing papers by Tuan Vu

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Tuan Vu. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Tuan Vu. The network helps show where Tuan Vu may publish in the future.

Co-authorship network of co-authors of Tuan Vu

This figure shows the co-authorship network connecting the top 25 collaborators of Tuan Vu. A scholar is included among the top collaborators of Tuan Vu based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Tuan Vu. Tuan Vu is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Hewamadduma, Channa, Miriam Freimer, Angela Genge, et al.. (2025). Changes in corticosteroid and non-steroidal immunosuppressive therapy with long-term zilucoplan treatment in generalized myasthenia gravis. Journal of Neurology. 272(7). 457–457. 2 indexed citations

Chahin, Nizar, Charles A. Stewart, Christopher M. Jewell, et al.. (2025). Durability of Response to B‐Cell Maturation Antigen‐Directed mRNA Cell Therapy in Myasthenia Gravis. Annals of Clinical and Translational Neurology. 12(11). 2358–2366.

Bhat, RameshM, et al.. (2025). Transdermal Drug Delivery Systems in Atopic Dermatitis: A Review of Vehicle Innovation and Skin Barrier Challenges. Cureus. 17(10). e94120–e94120.

Vu, Tuan, Renato Mantegazza, Djillali Annane, et al.. (2024). 506VP Long-term efficacy and safety of ravulizumab in adults with AChR-Ab+ gMG: final results from the phase 3 CHAMPION MG open-label extension. Neuromuscular Disorders. 43. 104441.639–104441.639.

Habib, Ali A., Henry J. Kaminski, Julian Großkreutz, et al.. (2024). Clinically Meaningful Improvement in Physical Fatigue and Muscle Weakness Fatigability with Rozanolixizumab: Post-hoc Analysis of MG Symptoms PRO Responder Rate in the MycarinG study (P4-11.001). Neurology. 102(7_supplement_1). 3311–3311. 1 indexed citations

Li, Guoping, Tuan Vu, D. S. Korobko, et al.. (2023). P276 Long-term safety, and efficacy of subcutaneous Efgartigimod PH20 in patients with generalized myasthenia gravis: interim results of ADAPT-SC+. Neuromuscular Disorders. 33. S179–S179. 2 indexed citations

Vu, Tuan, Andreas Meisel, Renato Mantegazza, et al.. (2023). Summary of Research: Terminal Complement Inhibitor Ravulizumab in Generalized Myasthenia Gravis. Neurology and Therapy. 12(5). 1435–1438. 14 indexed citations

Bril, Vera, John Vissing, Artur Drużdż, et al.. (2023). Rozanolixizumab responder and minimal symptom expression rates in generalized myasthenia gravis: Pooled phase 3 and extension studies. Journal of the Neurological Sciences. 455. 122016–122016. 1 indexed citations

Bril, Vera, James F. Howard, Chafic Karam, et al.. (2023). Effect of efgartigimod on muscle group subdomains in participants with generalized myasthenia gravis: post hoc analyses of the phase 3 pivotal ADAPT study. European Journal of Neurology. 31(1). e16098–e16098. 12 indexed citations

10.

G, Li, Yuebing Li, Tuan Vu, et al.. (2023). Dose Selection and Clinical Development of Efgartigimod PH20 Subcutaneous in Patients with Generalized Myasthenia Gravis (P1-5.017). Neurology. 100(17_supplement_2). 1 indexed citations

11.

Saccà, Francesco, Carolina Barnett, Tuan Vu, et al.. (2023). Efgartigimod improved health-related quality of life in generalized myasthenia gravis: results from a randomized, double-blind, placebo-controlled, phase 3 study (ADAPT). Journal of Neurology. 270(4). 2096–2105. 25 indexed citations

12.

Vu, Tuan, Stephan Ortiz, Masahisa Katsuno, et al.. (2022). Pharmacokinetics and Pharmacodynamics of Ravulizumab in Adults with Generalized Myasthenia Gravis: Results from the Phase 3 CHAMPION MG Study (P3-1.002). Neurology. 98(18_supplement). 2 indexed citations

13.

Vu, Tuan, Andreas Meisel, Renato Mantegazza, et al.. (2022). Efficacy and Safety of Ravulizumab, a Long-acting Terminal Complement Inhibitor, in Adults with Anti-Acetylcholine Receptor Antibody-Positive Generalized Myasthenia Gravis: Results from the Phase 3 CHAMPION MG Study (P1-1.Virtual). Neurology. 98(18_supplement). 4 indexed citations

14.

Ruzhansky, Katherine, Neelam Goyal, Suraj Muley, & Tuan Vu. (2022). Treatment Burden According to Patients with Generalized Myasthenia Gravis (P6-13.008). Neurology. 98(18_supplement). 1 indexed citations

15.

Howard, James F., Vera Bril, Tuan Vu, et al.. (2021). Efficacy, Safety, and Tolerability of Efgartigimod in Patients With Generalized Myasthenia Gravis: Analysis of the Phase 3 ADAPT Study (4520). Neurology. 96(15_supplement). 9 indexed citations

16.

Lee, Roland, et al.. (2021). Contrast-enhanced ultrasound for screening hepatocellular carcinoma: an implemented program at a semi-rural academic center. Abdominal Radiology. 46(9). 4170–4177. 6 indexed citations

17.

Muppidi, Srikanth, Kimiaki Utsugisawa, Michael Benatar, et al.. (2019). Long‐term safety and efficacy of eculizumab in generalized myasthenia gravis. Muscle & Nerve. 60(1). 14–24. 175 indexed citations

18.

Zesiewicz, Theresa A., Seok Hun Kim, Kelly L. Sullivan, et al.. (2014). Treatment of Neurodegenerative Ataxias With Intravenous Immune Globulin. Journal of Neurology Research. 4(4). 97–100. 1 indexed citations

19.

Bonilla, E., Kurenai Tanji, Michio Hirano, et al.. (1999). Mitochondrial involvement in Alzheimer’s disease. Biochimica et Biophysica Acta (BBA) - Bioenergetics. 1410(2). 171–182. 139 indexed citations

20.

Vu, Tuan, Arthur D. Weissman, & Edythe D. London. (1990). Pharmacological Characteristics and Distributions of σ and Phencyclidine Receptors in the Animal Kingdom. Journal of Neurochemistry. 54(2). 598–604. 21 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact